Dominantly inherited alzheimer network: Facilitating research and clinical trials

Alzheimer's Research and Therapy

Volumn 5, Issue 5, 2013, Pages

  Moulder, Krista L ^a   Snider, B Joy ^a   Mills, Susan L ^a   Buckles, Virginia D ^a   Santacruz, Anna M ^a   Bateman, Randall J ^a   Morris, John C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE INHIBITOR; GANTENERUMAB; PRESENILIN 1; PRESENILIN 2; SOLANEZUMAB;

ALZHEIMER DISEASE; BRAIN SIZE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DOMINANTLY INHERITED ALZHEIMER NETWORK; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE UTILIZATION; LONGITUDINAL STUDY; MEDICAL RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGISTER; REVIEW; SECONDARY PREVENTION;

EID: 84887856825     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt213     Document Type: Review

References (43)

1. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Hebert LE, Weuve J, Scherr PA, Evans DA, Neurology 2013 80 1778 1783 10.1212/WNL.0b013e31828726f5 23390181
2. Tejada-Vera B, Mortality From Alzheimer's Disease in the United States: Data for 2000 and 2010. NCHS data brief, no. 116 National Center for Health Statistics: Hyattsville, MD 2013
3. Alzheimer's disease: the challenge of the second century. Holtzman DM, Morris JC, Goate AM, Sci Transl Med 2011 77 77sr1
4. Testing the right target and right drug at the right stage. Sperling RA, Jack CR, Aisen PS, Sci Transl Med 2011 3 111cm33 10.1126/scitranslmed.3002609 22133718
5. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC, Neurobiol Aging 2009 30 1026 1036 10.1016/j.neurobiolaging.2009.04. 002 19376612
6. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Price JL, Morris JC, Annals Neurol 1999 45 358 368 10.1002/1531- 8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X (Pubitemid 29120041)
7. Neuropathology of cognitively normal elderly. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC, J Neuropathol Exp Neurol 2003 62 1087 1095 14656067 (Pubitemid 37413820)
8. Neuropathology of older persons without cognitive impairment from two community-based studies. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS, Neurology 2006 66 1837 1844 10.1212/01.wnl.0000219668.47116.e6 16801647 (Pubitemid 44049813)
9. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW Jr, Morris JC, Arch Neurol 2001 58 1395 1402 10.1001/archneur.58.9.1395 11559310 (Pubitemid 32845990)
10. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT, J Neurosci 1996 16 4491 4500 8699259 (Pubitemid 26243044)
11. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Monsell SE, Mock C, Roe CM, Ghoshal N, Morris JC, Cairns NJ, Kukull W, Neurology 2013 80 2121 2129 10.1212/WNL.0b013e318295d7a1 23645594
12. Cerebrospinal fluid tau/β-amyloid 42 ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM, Roe CM, Xiong C, Morris JC, Holtzman DM, Arch Neurol 2007 64 343 349 10.1001/archneur.64.3.noc60123 17210801 (Pubitemid 46425688)
13. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer's disease. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA, Arch Neurol 2009 66 1469 1475 10.1001/archneurol.2009.269 20008650
14. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC, Annals Neurol 2011 69 181 192 10.1002/ana.22248
15. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ, Lancet Neurol 2013 12 207 216 10.1016/S1474-4422(12)70291-0 23332364
16. Alzheimer's disease and Parkinson's disease. Nussbaum RL, Ellis CE, N Engl J Med 2003 348 1356 1364 10.1056/NEJM2003ra020003 12672864 (Pubitemid 36384104)
17. Novel Presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW, Morris JC, Arch Neurol 2005 62 1821 1830 10.1001/archneur.62.12.1821 16344340 (Pubitemid 41785075)
18. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Bateman RJ, Aisen PS, Strooper BD, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C, Alzheimers Res Ther 2011 3 1 21211070
19. Familial Alzheimer's disease: site of mutation influences clinical phenotype. Lippa CF, Swearer JM, Kane KJ, Nochlin D, Bird TD, Ghetti B, Nee LE, St George-Hyslop P, Pollen DA, Drachman DA, Annals Neurol 2000 48 376 379 10.1002/1531-8249(200009)48:3<376::AID-ANA13>3.0.CO;2-U
20. Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. Mullan M, Houlden H, Crawford F, Kennedy A, Rogues P, Rossor M, Am J Med Genet Neuropsychiat Genet 1993 48 129 130 10.1002/ajmg.1320480303 (Pubitemid 23292005)
21. Locus-specific mutation databases for neurodegenerative brain diseases. Cruts M, Theuns J, Van Broeckhoven C, Hum Mutat 2012 33 1340 1344 10.1002/humu.22117 22581678
22. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease: a longitudinal prospective study. Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN, Brain 1998 121 1631 1639 10.1093/brain/121.9. 1631 9762953 (Pubitemid 28419970)
23. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. Mosconi L, Sorbi S, de Leon MJ, Nacmias B, Myoung PS, Tsui W, Ginestroni A, Bessi V, Fayyazz M, Caffarra P, Pupi A, J Nucl Med 2006 47 1778 1786 17079810 (Pubitemid 47553729)
24. What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review. Ringman JM, J Geriatr Psychiatry Neurol 2005 18 228 233 10.1177/0891988705281878 16306245 (Pubitemid 41736389)
25. Acceleration of cortical thinning in familial Alzheimer's disease. Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, Fox NC, Neurobiol Aging 2011 32 1765 1773 10.1016/j.neurobiolaging.2009.11.013 20005601
26. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Maréchal L, Martinaud O, Pariente J, Puel M, Rollin-Sillaire A, Pasquier F, Le Ber I, Sarazin M, Croisile B, Boutoleau-Bretonnière C, Thomas-Antérion C, Paquet C, Moreaud O, Gabelle A, Sellal F, Sauvée M, Laquerrière A, Duyckaerts C, Delisle MB, Streichenberger N, Lannes B, Frebourg T, Hannequin D, Campion D, J Alzheimers Dis 2012 30 847 856 22475797
27. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapíe L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS, JAMA 1997 277 793 799 10.1001/jama.1997.03540340027028 9052708 (Pubitemid 27111314)
28. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM, Lancet Neurol 2012 11 1057 1065 10.1016/S1474-4422(12) 70227-2 23137949
29. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F, Lancet Neurol 2012 11 1048 1056 10.1016/S1474-4422(12)70228-4 23137948
30. Dominantly Inherited Alzheimer Network home page http://dian-info.org/
31. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD, Clin Invest 2012 2 975 984 10.4155/cli.12.93
32. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, N Engl J Med 2012 367 795 804 10.1056/NEJMoa1202753 22784036
33. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Alz Dement 2011 7 280 292 10.1016/j.jalz.2011.03.003
34. The diagnosis of mild cognitive impairment due to Alzheimer disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH, Alz Dement 2011 7 270 279 10.1016/j.jalz.2011.03.008
35. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. McKhann GM, Knopman DS, Chertkow H, Hynes M, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, Alz Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005
36. 'Will I get Alzheimer disease?' when cognitively normal patients ask to be tested for Alzheimer disease. Snider BJ, Buckles VD, Continuum 2013 19 470 474 23558490
37. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S, Nat Med 1996 2 864 870 10.1038/nm0896-864 8705854 (Pubitemid 26296755)
38. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B, EMBO 2010 29 3408 3420 10.1038/emboj.2010.211
39. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Bateman RJ, Klunk WE, Neurotherapeutics 2008 5 381 390 10.1016/j.nurt.2008.05.009 18625449 (Pubitemid 351952493)
40. Dominantly Inherited Alzheimer's Network (DIAN) Expanded Registry Pharma Consortium Members http://dianxr.org/pharma.htm
41. Dominantly Inherited Alzheimer's Network (DIAN) Expanded Registry http://www.dianxr.org/
42. Can we prevent Alzheimer's disease? Secondary 'prevention' trials in Alzheimer's disease. Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA, Alz Dement 2013 9 123 131 10.1016/j.jalz.2012.12.004
43. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN, J Alz Dis 2011 26S3 321 329